SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1692)7/2/2003 5:06:28 PM
From: Icebrg  Read Replies (2) | Respond to of 3044
 
>>Full article from Medscape on the cost effectiveness of the three glycoprotein IIb/IIIa-receptor inhibitors versus controls:>>

And if you don't have time to read the article just now, just click on the "Add to my Shortcuts" and Medscape will remember for you what you would like to revisit.

Erik



To: tuck who wrote (1692)7/3/2003 3:17:39 PM
From: keokalani'nui  Read Replies (1) | Respond to of 3044
 
Thanks Tuck. Interesting. Just to save others the time:

Reopro wins
Integrillin second
Aggrastat third



To: tuck who wrote (1692)7/6/2003 2:36:57 PM
From: microcapfun  Respond to of 3044
 
Reopro

Message #1692 from tuck at Jul 2, 2003 4:48 PM

Full article from Medscape on the cost effectiveness of the three glycoprotein IIb/IIIa-receptor inhibitors versus controls:
medscape.com

Free registration may be needed (and is recommended).

Cheers, Tuck

Don't know if people noticed this at the bottom of the article:

Funding Information

Supported by Eli Lilly & Co.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News